Medical researchers are happy to close out the year with good news regarding a new drug to treat high blood pressure.
The FDA recently announced the approval of two procedures and devices that should prove helpful to people with treatment-resistant hypertension.
The two recently approved devices are Medtronic’s Symplicity Spyral Renal Denervation system and the Recor Medical’s Paradise Ultrasound Renal Denervation system.
The insertion of the devices requires a minimally invasive procedure. The devices, which are inserted near the kidneys, are designed to control overstimulated sympathetic nerves — an issue that leads to high blood pressure.
The device is activated when medications designed to control hypertension fail.
Dr. Samin Sharma, a cardiologist and the Director of the Mount Sinai Cardiovascular Clinical Institute at Mount Sinai Fuster Heart Hospital in New York City, reports that procedures have been marked by great success.
Sharma told Fox News that according to the FDA’s approval report, “The device will reduce blood pressure as an adjunctive treatment in patients with hypertension in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure.”
The one-hour procedure, which will control high blood pressure for five years, will reportedly greatly reduce the risk of heart attack, stroke, brain bleeds and kidney failure.
Sharma clarified the procedure is not recommended for all patients, but can be helpful for those who do NOT show blockage of the kidney arteries.
The procedure involves a cardiologist inserting a thin tube into the renal artery. The tube sends a control signal to sympathetic nerves connected to the kidney, signaling that those nerves are not functioning properly.
The signal is similar to a sound wave or radiofrequency energy wave.
This “calms the nerves,” Sharma explained.
Though there are risks with any medical procedure, Sharma reported the risk associated with this procedure is low and the potential benefit is high.
Scroll down to leave a comment and share your thoughts.